Eli Lilly's (LLY) Reaction to Disappointing Evacetrapib Data Appears 'Overdone', Says BofA/ML
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $732.20 --0%
Rating Summary:
25 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 5 | New: 2
Rating Summary:
25 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 5 | New: 2
Join SI Premium – FREE
BofA/Merrill Lynch maintained a Buy rating on Eli Lilly (NYSE: LLY) but lowered its price target to $104.00 (from $108.00). Analyst Colin Bristow said while he expected the stock to react negatively to news Lilly halted development of evacetrapib, the initial reaction appears overdone and beyond the consensus NPV contribution of evacetrapib. Consensus was for peak sales of around $800 million, the report noted.
For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.
Shares of Eli Lilly closed at $86.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Senate Committee Investigates Ozempic and Wegovy Costs - NYT
- Helen of Troy (HELE) PT Raised to $151 at DA Davidson
- Mr. Cooper Group Inc. (COOP) PT Raised to $90 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
